25 XP   0   0   10

Ideaya Biosciences Inc
Buy, Hold or Sell?

Let's analyse Ideaya Biosciences Inc together

PenkeI guess you are interested in Ideaya Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ideaya Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ideaya Biosciences Inc

I send you an email if I find something interesting about Ideaya Biosciences Inc.

Quick analysis of Ideaya Biosciences Inc (30 sec.)










What can you expect buying and holding a share of Ideaya Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
9.5%

What is your share worth?

Current worth
$8.33
Expected worth in 1 year
$16.66
How sure are you?
52.4%

+ What do you gain per year?

Total Gains per Share
$8.33
Return On Investment
21.3%

For what price can you sell your share?

Current Price per Share
$39.02
Expected price per share
$30.12 - $46.40
How sure are you?
50%

1. Valuation of Ideaya Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)

$39.02

Intrinsic Value Per Share

$-16.97 - $-19.92

Total Value Per Share

$-8.64 - $-11.59

2. Growth of Ideaya Biosciences Inc (5 min.)




Is Ideaya Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$621m$231.6m$50.5m17.9%

How much money is Ideaya Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$27.3m-$14.7m-$12.5m-46.1%
Net Profit Margin-562.3%-266.3%--

How much money comes from the company's main activities?

3. Financial Health of Ideaya Biosciences Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#87 / 1010

Most Revenue
#335 / 1010

Most Profit
#761 / 1010

Most Efficient
#753 / 1010

What can you expect buying and holding a share of Ideaya Biosciences Inc? (5 min.)

Welcome investor! Ideaya Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Ideaya Biosciences Inc.

What can you expect buying and holding a share of Ideaya Biosciences Inc?

First you should know what it really means to hold a share of Ideaya Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Ideaya Biosciences Inc is $39.02. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ideaya Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ideaya Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $8.33. Based on the TTM, the Book Value Change Per Share is $2.08 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ideaya Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.46-1.2%-0.38-1.0%-0.20-0.5%-0.20-0.5%-0.21-0.5%
Usd Book Value Change Per Share1.523.9%2.085.3%0.000.0%0.451.2%0.401.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.040.1%0.040.1%
Usd Total Gains Per Share1.523.9%2.085.3%0.000.0%0.491.3%0.431.1%
Usd Price Per Share35.58-24.95-14.52-16.14-15.37-
Price to Earnings Ratio-19.53--16.09-32.92--12.70--12.10-
Price-to-Total Gains Ratio23.47-13.71--10.70-11.15-11.15-
Price to Book Ratio4.27-2.06-2.43-2.99-2.85-
Price-to-Total Gains Ratio23.47-13.71--10.70-11.15-11.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share39.02
Number of shares25
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share2.080.45
Usd Total Gains Per Share2.080.49
Gains per Quarter (25 shares)52.0612.22
Gains per Year (25 shares)208.2548.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1020819844539
2041740689088
3062561412135137
4083382216180186
501041103020225235
601250123824270284
701458144628315333
801666165431359382
901874186235404431
1002083207039449480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.020.00.04.8%1.020.00.04.8%
Book Value Change Per Share2.00.02.050.0%7.03.02.058.3%11.06.03.055.0%11.07.03.052.4%11.07.03.052.4%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.019.09.5%2.00.019.09.5%
Total Gains per Share2.00.02.050.0%7.03.02.058.3%11.06.03.055.0%11.07.03.052.4%11.07.03.052.4%

Fundamentals of Ideaya Biosciences Inc

About Ideaya Biosciences Inc

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-11 11:29:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ideaya Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ideaya Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ideaya Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -865.5% means that $-8.66 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ideaya Biosciences Inc:

  • The MRQ is -865.5%. The company is making a huge loss. -2
  • The TTM is -562.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-865.5%TTM-562.3%-303.2%
TTM-562.3%YOY-266.3%-296.0%
TTM-562.3%5Y-220.6%-341.8%
5Y-220.6%10Y-210.0%-10.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-865.5%-200.1%-665.4%
TTM-562.3%-216.8%-345.5%
YOY-266.3%-288.3%+22.0%
5Y-220.6%-449.1%+228.5%
10Y-210.0%-605.5%+395.5%
1.1.2. Return on Assets

Shows how efficient Ideaya Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ideaya Biosciences Inc to the Biotechnology industry mean.
  • -5.2% Return on Assets means that Ideaya Biosciences Inc generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ideaya Biosciences Inc:

  • The MRQ is -5.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.2%TTM-5.3%+0.1%
TTM-5.3%YOY-4.1%-1.2%
TTM-5.3%5Y-5.5%+0.2%
5Y-5.5%10Y-5.7%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.2%-13.3%+8.1%
TTM-5.3%-12.8%+7.5%
YOY-4.1%-11.7%+7.6%
5Y-5.5%-13.9%+8.4%
10Y-5.7%-15.7%+10.0%
1.1.3. Return on Equity

Shows how efficient Ideaya Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ideaya Biosciences Inc to the Biotechnology industry mean.
  • -5.5% Return on Equity means Ideaya Biosciences Inc generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ideaya Biosciences Inc:

  • The MRQ is -5.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-5.6%+0.1%
TTM-5.6%YOY-5.0%-0.6%
TTM-5.6%5Y-6.4%+0.8%
5Y-6.4%10Y-6.1%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%-16.9%+11.4%
TTM-5.6%-16.1%+10.5%
YOY-5.0%-15.1%+10.1%
5Y-6.4%-19.3%+12.9%
10Y-6.1%-20.2%+14.1%

1.2. Operating Efficiency of Ideaya Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ideaya Biosciences Inc is operating .

  • Measures how much profit Ideaya Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ideaya Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of -1,068.5% means the company generated $-10.68  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ideaya Biosciences Inc:

  • The MRQ is -1,068.5%. The company is operating very inefficient. -2
  • The TTM is -698.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,068.5%TTM-698.8%-369.7%
TTM-698.8%YOY-288.2%-410.6%
TTM-698.8%5Y-253.9%-444.8%
5Y-253.9%10Y-241.8%-12.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,068.5%-296.2%-772.3%
TTM-698.8%-232.5%-466.3%
YOY-288.2%-298.2%+10.0%
5Y-253.9%-492.1%+238.2%
10Y-241.8%-632.4%+390.6%
1.2.2. Operating Ratio

Measures how efficient Ideaya Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 11.95 means that the operating costs are $11.95 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ideaya Biosciences Inc:

  • The MRQ is 11.945. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.052. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ11.945TTM8.052+3.894
TTM8.052YOY4.006+4.045
TTM8.0525Y3.266+4.786
5Y3.26610Y3.110+0.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.9453.231+8.714
TTM8.0523.310+4.742
YOY4.0063.890+0.116
5Y3.2665.739-2.473
10Y3.1107.876-4.766

1.3. Liquidity of Ideaya Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ideaya Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.65 means the company has $19.65 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ideaya Biosciences Inc:

  • The MRQ is 19.654. The company is very able to pay all its short-term debts. +2
  • The TTM is 17.651. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.654TTM17.651+2.002
TTM17.651YOY8.221+9.431
TTM17.6515Y12.346+5.306
5Y12.34610Y12.556-0.210
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.6543.890+15.764
TTM17.6514.173+13.478
YOY8.2215.344+2.877
5Y12.3466.126+6.220
10Y12.5566.448+6.108
1.3.2. Quick Ratio

Measures if Ideaya Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ideaya Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 36.93 means the company can pay off $36.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ideaya Biosciences Inc:

  • The MRQ is 36.926. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 31.737. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ36.926TTM31.737+5.189
TTM31.737YOY14.506+17.231
TTM31.7375Y19.961+11.776
5Y19.96110Y20.413-0.452
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.9263.514+33.412
TTM31.7373.998+27.739
YOY14.5065.380+9.126
5Y19.9616.105+13.856
10Y20.4136.404+14.009

1.4. Solvency of Ideaya Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ideaya Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ideaya Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Ideaya Biosciences Inc assets are financed with 4.3% credit (debt) and the remaining percentage (100% - 4.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ideaya Biosciences Inc:

  • The MRQ is 0.043. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.523. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.043TTM0.523-0.479
TTM0.523YOY0.375+0.147
TTM0.5235Y0.443+0.079
5Y0.44310Y0.494-0.051
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0430.339-0.296
TTM0.5230.336+0.187
YOY0.3750.271+0.104
5Y0.4430.366+0.077
10Y0.4940.389+0.105
1.4.2. Debt to Equity Ratio

Measures if Ideaya Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ideaya Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.5% means that company has $0.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ideaya Biosciences Inc:

  • The MRQ is 0.045. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.560. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.045TTM0.560-0.514
TTM0.560YOY0.431+0.129
TTM0.5605Y0.550+0.010
5Y0.55010Y0.524+0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0450.388-0.343
TTM0.5600.402+0.158
YOY0.4310.335+0.096
5Y0.5500.426+0.124
10Y0.5240.461+0.063

2. Market Valuation of Ideaya Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ideaya Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Ideaya Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -19.53 means the investor is paying $-19.53 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ideaya Biosciences Inc:

  • The EOD is -21.421. Based on the earnings, the company is expensive. -2
  • The MRQ is -19.532. Based on the earnings, the company is expensive. -2
  • The TTM is -16.093. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-21.421MRQ-19.532-1.888
MRQ-19.532TTM-16.093-3.439
TTM-16.093YOY32.915-49.008
TTM-16.0935Y-12.701-3.392
5Y-12.70110Y-12.096-0.605
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-21.421-2.264-19.157
MRQ-19.532-2.629-16.903
TTM-16.093-2.680-13.413
YOY32.915-4.145+37.060
5Y-12.701-6.257-6.444
10Y-12.096-6.254-5.842
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ideaya Biosciences Inc:

  • The EOD is -29.583. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -26.975. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -16.312. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-29.583MRQ-26.975-2.608
MRQ-26.975TTM-16.312-10.663
TTM-16.312YOY-11.908-4.404
TTM-16.3125Y-16.482+0.170
5Y-16.48210Y-15.697-0.785
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-29.583-2.973-26.610
MRQ-26.975-3.333-23.642
TTM-16.312-3.553-12.759
YOY-11.908-5.605-6.303
5Y-16.482-8.376-8.106
10Y-15.697-8.865-6.832
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ideaya Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.27 means the investor is paying $4.27 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ideaya Biosciences Inc:

  • The EOD is 4.684. Based on the equity, the company is fair priced.
  • The MRQ is 4.271. Based on the equity, the company is fair priced.
  • The TTM is 2.058. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.684MRQ4.271+0.413
MRQ4.271TTM2.058+2.214
TTM2.058YOY2.432-0.374
TTM2.0585Y2.991-0.933
5Y2.99110Y2.848+0.142
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.6841.896+2.788
MRQ4.2712.115+2.156
TTM2.0582.093-0.035
YOY2.4322.884-0.452
5Y2.9913.542-0.551
10Y2.8483.916-1.068
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ideaya Biosciences Inc.

3.1. Institutions holding Ideaya Biosciences Inc

Institutions are holding 102.619% of the shares of Ideaya Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc7.29160.0049543666884309518.3538
2023-09-30Bvf Inc7.08623.84395283489-400000-7.0379
2023-12-31Federated Hermes Inc5.20890.3431388377550004614.778
2023-12-31T. Rowe Price Associates, Inc.4.78310.0171356627853590917.6846
2023-12-31HHG PLC4.76380.075435518911828731106.1266
2023-12-31Vanguard Group Inc4.66170.0027347577250427516.9704
2023-12-31State Street Corporation4.01270.0052299189984439939.3201
2023-12-31Adage Capital Partners Gp LLC3.92310.2155292509463813327.9031
2023-09-30Canaan Partners X LLC3.568596.0629266071300
2023-09-30Deerfield Management Co3.04271.3485226862800
2023-12-31Boxer Capital LLC2.95443.9064220281200
2023-12-31Capital Research Global Investors2.65140.0173197687060000043.5771
2023-12-31Logos Global Management LP2.41425.97811800000-450000-20
2023-12-31Avidity Partners Management LP2.03861.97091520000-624971-29.1366
2023-12-31Sofinnova Ventures1.95662.9045145888142169440.6575
2023-12-31Geode Capital Management, LLC1.81240.005135133719023216.3837
2023-12-31Dimensional Fund Advisors, Inc.1.72520.0134128630014405812.6119
2023-12-31Morgan Stanley - Brokerage Accounts1.65410.003912332711000495429.8102
2023-12-31Baker Bros Advisors LP1.42450.43106212300
2023-09-30Holocene Advisors, LP1.38540.122103293110329310
Total 68.3591117.270750968732+7609027+14.9%

3.2. Funds holding Ideaya Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Growth Compy Commingled Pl O4.22450.1912314980031498000
2024-01-31Fidelity Growth Company Fund3.19880.1893238500023850000
2023-12-31Federated Hermes Kaufmann Small Cap A2.8141.7751209810022810012.1979
2023-12-31Federated Hermes Kaufmann Small Cap Grow2.8141.7751209810022810012.1979
2024-02-29Vanguard Total Stock Mkt Idx Inv2.49660.00541861484-6336-0.3392
2024-02-29SPDR® S&P Biotech ETF2.43761.02591817472339601.9041
2023-12-31American Funds SMALLCAP World A2.38560.0879177874060000050.9018
2023-12-31Federated Hermes Kaufmann Growth2.33491.2702174090026520017.9711
2023-12-31Federated Hermes Kaufmann R2.33491.2701174090026520017.9711
2023-12-31T. Rowe Price New Horizons2.30990.247717222631323008.3209
2023-12-31US Small-Cap Growth II Equity Comp2.30990.246817222631323008.3209
2024-02-29iShares Russell 2000 ETF1.950.10421453954-238-0.0164
2024-01-31Fidelity Select Biotechnology1.62141.1408120895733000037.5445
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.29650.0423966670-872-0.0901
2024-01-31Fidelity Growth Company K61.01170.19597543007543000
2023-12-31Janus Henderson Triton D0.97960.38117303947303940
2023-12-31Janus Henderson US SMID Cap Growth0.97960.38277303947303940
2023-12-31Janus Henderson Global Life Sciences0.96640.523472058530483573.3217
2023-12-31Janus Henderson Global Life Sciences D0.96640.52172058530483573.3217
2024-01-31Fidelity Series Growth Company0.83530.18246228006228000
Total 40.267611.558530023661+11190072+37.3%

3.3. Insider Transactions

Insiders are holding 0.982% of the shares of Ideaya Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-09Yujiro S HataSELL2355745.54
2024-02-09Briseno Andres RuizSELL200046.02
2024-01-22Briseno Andres RuizSELL200042.03
2024-01-16Yujiro S HataSELL6273940.17
2024-01-12Briseno Andres RuizSELL200038.01
2024-01-12Yujiro S HataSELL1226140.04
2023-12-15Yujiro S HataSELL7500035.03
2023-12-14Briseno Andres RuizSELL200034
2023-11-03Jason ThroneSELL516330.09
2023-09-12Jason ThroneSELL100030
2023-09-05Jason ThroneSELL173730.03
2023-09-01Jason ThroneSELL210030.03
2023-08-29Paul A StoneSELL500028.87
2023-08-21Paul A StoneSELL97826.4
2023-08-18Paul A StoneSELL382226.38
2023-08-16Paul A StoneSELL20026.43
2023-08-09Jason ThroneSELL500025.09
2023-08-09Paul A StoneSELL250025.05
2023-07-10Jason ThroneSELL948523
2023-05-31Jason ThroneSELL43223

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Ideaya Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.5162.083-27%-+100%0.449+237%0.397+282%
Book Value Per Share--8.3303.786+120%3.107+168%2.293+263%2.153+287%
Current Ratio--19.65417.651+11%8.221+139%12.346+59%12.556+57%
Debt To Asset Ratio--0.0430.523-92%0.375-88%0.443-90%0.494-91%
Debt To Equity Ratio--0.0450.560-92%0.431-89%0.550-92%0.524-91%
Dividend Per Share----0%-0%0.039-100%0.037-100%
Eps---0.455-0.379-17%-0.197-57%-0.200-56%-0.212-53%
Free Cash Flow Per Share---0.330-0.394+20%-0.304-8%-0.169-49%-0.166-50%
Free Cash Flow To Equity Per Share--1.5600.822+90%0.022+7006%0.357+337%0.335+366%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---19.924--------
Intrinsic Value_10Y_min---16.970--------
Intrinsic Value_1Y_max---1.310--------
Intrinsic Value_1Y_min---1.287--------
Intrinsic Value_3Y_max---4.460--------
Intrinsic Value_3Y_min---4.247--------
Intrinsic Value_5Y_max---8.240--------
Intrinsic Value_5Y_min---7.603--------
Market Cap2909343062.080+9%2652855616.3201860093184.040+43%1082615614.080+145%1203552427.168+120%1146240406.827+131%
Net Profit Margin---8.655-5.623-35%-2.663-69%-2.206-75%-2.100-76%
Operating Margin---10.685-6.988-35%-2.882-73%-2.539-76%-2.418-77%
Operating Ratio--11.9458.052+48%4.006+198%3.266+266%3.110+284%
Pb Ratio4.684+9%4.2712.058+108%2.432+76%2.991+43%2.848+50%
Pe Ratio-21.421-10%-19.532-16.093-18%32.915-159%-12.701-35%-12.096-38%
Price Per Share39.020+9%35.58024.948+43%14.520+145%16.142+120%15.373+131%
Price To Free Cash Flow Ratio-29.583-10%-26.975-16.312-40%-11.908-56%-16.482-39%-15.697-42%
Price To Total Gains Ratio25.737+9%23.46813.714+71%-10.696+146%11.149+110%11.149+110%
Quick Ratio--36.92631.737+16%14.506+155%19.961+85%20.413+81%
Return On Assets---0.052-0.053+1%-0.041-21%-0.055+5%-0.057+8%
Return On Equity---0.055-0.056+3%-0.050-9%-0.064+17%-0.061+11%
Total Gains Per Share--1.5162.083-27%-+100%0.489+210%0.434+249%
Usd Book Value--621090000.000282284750.000+120%231689250.000+168%170970750.000+263%160498428.571+287%
Usd Book Value Change Per Share--1.5162.083-27%-+100%0.449+237%0.397+282%
Usd Book Value Per Share--8.3303.786+120%3.107+168%2.293+263%2.153+287%
Usd Dividend Per Share----0%-0%0.039-100%0.037-100%
Usd Eps---0.455-0.379-17%-0.197-57%-0.200-56%-0.212-53%
Usd Free Cash Flow---24586000.000-29398000.000+20%-22654500.000-8%-12614800.000-49%-12384809.524-50%
Usd Free Cash Flow Per Share---0.330-0.394+20%-0.304-8%-0.169-49%-0.166-50%
Usd Free Cash Flow To Equity Per Share--1.5600.822+90%0.022+7006%0.357+337%0.335+366%
Usd Market Cap2909343062.080+9%2652855616.3201860093184.040+43%1082615614.080+145%1203552427.168+120%1146240406.827+131%
Usd Price Per Share39.020+9%35.58024.948+43%14.520+145%16.142+120%15.373+131%
Usd Profit---33955000.000-27340500.000-19%-14748000.000-57%-14729300.000-57%-14435619.048-57%
Usd Revenue--3923000.0005846250.000-33%12732750.000-69%6089800.000-36%5799809.524-32%
Usd Total Gains Per Share--1.5162.083-27%-+100%0.489+210%0.434+249%
 EOD+6 -2MRQTTM+20 -14YOY+19 -155Y+21 -1510Y+21 -15

4.2. Fundamental Score

Let's check the fundamental score of Ideaya Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-21.421
Price to Book Ratio (EOD)Between0-14.684
Net Profit Margin (MRQ)Greater than0-8.655
Operating Margin (MRQ)Greater than0-10.685
Quick Ratio (MRQ)Greater than136.926
Current Ratio (MRQ)Greater than119.654
Debt to Asset Ratio (MRQ)Less than10.043
Debt to Equity Ratio (MRQ)Less than10.045
Return on Equity (MRQ)Greater than0.15-0.055
Return on Assets (MRQ)Greater than0.05-0.052
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Ideaya Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.965
Ma 20Greater thanMa 5041.314
Ma 50Greater thanMa 10043.578
Ma 100Greater thanMa 20040.501
OpenGreater thanClose38.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Other Current Assets  5,414-1,3944,0203,8927,912-1,1846,728-639,334-632,606
Inventory  -8,3173,829-4,488-11,889-16,377-26,017-42,394575,008532,614
Accumulated Other Comprehensive Income  -2,8711,466-1,405226-1,179429-7501,312562
Income Tax Expense  -2,242-1,357-3,5992,601-998-28-1,0266,6495,623



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets649,316
Total Liabilities28,226
Total Stockholder Equity621,090
 As reported
Total Liabilities 28,226
Total Stockholder Equity+ 621,090
Total Assets = 649,316

Assets

Total Assets649,316
Total Current Assets532,632
Long-term Assets116,684
Total Current Assets
Cash And Cash Equivalents 157,018
Short-term Investments 368,096
Net Receivables 18
Inventory 532,614
Other Current Assets -632,606
Total Current Assets  (as reported)532,632
Total Current Assets  (calculated)425,140
+/- 107,492
Long-term Assets
Property Plant Equipment 8,410
Long Term Investments 107,492
Long-term Assets Other 782
Long-term Assets  (as reported)116,684
Long-term Assets  (calculated)116,684
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities27,101
Long-term Liabilities1,125
Total Stockholder Equity621,090
Total Current Liabilities
Short-term Debt 1,747
Accounts payable 6,598
Other Current Liabilities 18,756
Total Current Liabilities  (as reported)27,101
Total Current Liabilities  (calculated)27,101
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,125
Long-term Liabilities  (as reported)1,125
Long-term Liabilities  (calculated)1,125
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -348,364
Accumulated Other Comprehensive Income 562
Other Stockholders Equity 968,885
Total Stockholder Equity (as reported)621,090
Total Stockholder Equity (calculated)621,090
+/-0
Other
Capital Stock7
Cash and Short Term Investments 632,606
Common Stock Shares Outstanding 65,246
Liabilities and Stockholders Equity 649,316
Net Debt -154,146
Net Invested Capital 621,090
Net Working Capital 505,531
Property Plant and Equipment Gross 18,021
Short Long Term Debt Total 2,872



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
96,541
92,675
133,358
122,331
113,001
101,791
184,510
301,384
298,269
326,097
328,401
399,444
381,347
358,867
338,007
410,907
387,969
364,746
527,557
532,942
649,316
649,316532,942527,557364,746387,969410,907338,007358,867381,347399,444328,401326,097298,269301,384184,510101,791113,001122,331133,35892,67596,541000
   > Total Current Assets 
0
0
0
90,667
79,877
122,632
112,161
100,482
89,464
173,950
288,841
288,605
308,158
279,789
268,963
250,996
256,049
272,189
393,437
370,454
351,210
501,788
482,182
532,632
532,632482,182501,788351,210370,454393,437272,189256,049250,996268,963279,789308,158288,605288,841173,95089,464100,482112,161122,63279,87790,667000
       Cash And Cash Equivalents 
0
0
0
20,505
35,302
88,115
38,848
34,067
35,462
147,543
81,238
72,037
136,752
90,427
108,428
92,046
55,291
49,106
101,954
68,632
67,237
102,843
151,850
157,018
157,018151,850102,84367,23768,632101,95449,10655,29192,046108,42890,427136,75272,03781,238147,54335,46234,06738,84888,11535,30220,505000
       Short-term Investments 
0
0
0
69,456
43,718
32,048
70,508
64,889
52,401
22,871
197,445
211,548
165,569
183,749
156,123
154,724
197,308
219,514
284,290
296,197
272,233
390,873
316,901
368,096
368,096316,901390,873272,233296,197284,290219,514197,308154,724156,123183,749165,569211,548197,44522,87152,40164,88970,50832,04843,71869,456000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
1,877
2,922
1,325
1,018
1,103
697
288
3,449
211
468
160
6,703
18
186,7031604682113,4492886971,1031,0181,3252,9221,87700000000000
       Other Current Assets 
0
0
0
706
857
2,469
2,805
2,698
1,601
3,536
2,654
3,143
2,915
4,288
3,394
3,123
2,753
3,281
3,744
5,414
4,020
7,912
6,728
-632,606
-632,6066,7287,9124,0205,4143,7443,2812,7533,1233,3944,2882,9153,1432,6543,5361,6012,6982,8052,469857706000
   > Long-term Assets 
0
0
0
5,874
12,798
10,726
10,170
12,519
12,327
10,560
12,543
9,664
17,939
48,612
130,481
130,351
102,818
65,818
17,470
17,515
13,536
25,769
50,760
116,684
116,68450,76025,76913,53617,51517,47065,818102,818130,351130,48148,61217,9399,66412,54310,56012,32712,51910,17010,72612,7985,874000
       Property Plant Equipment 
0
0
0
5,152
10,874
10,595
10,046
9,699
9,165
8,883
9,610
9,476
9,642
9,461
8,941
8,661
8,828
10,367
9,527
8,993
8,828
8,562
7,539
8,410
8,4107,5398,5628,8288,9939,52710,3678,8288,6618,9419,4619,6429,4769,6108,8839,1659,69910,04610,59510,8745,152000
       Long Term Investments 
0
0
0
0
0
0
0
1,526
3,040
1,545
10,158
0
8,080
38,254
121,217
121,293
93,628
55,171
7,691
8,317
11,740
16,377
42,394
107,492
107,49242,39416,37711,7408,3177,69155,17193,628121,293121,21738,2548,080010,1581,5453,0401,5260000000
       Other Assets 
0
0
0
0
1,924
131
124
122
122
132
279
188
217
897
323
397
362
280
252
205
0
830
0
0
0083002052522803623973238972171882791321221221241311,9240000
> Total Liabilities 
0
0
0
145,489
12,346
12,750
11,925
113,001
12,688
12,452
301,384
298,269
92,971
88,141
81,815
381,347
70,200
68,686
42,138
387,969
364,746
527,557
24,893
28,226
28,22624,893527,557364,746387,96942,13868,68670,200381,34781,81588,14192,971298,269301,38412,45212,688113,00111,92512,75012,346145,489000
   > Total Current Liabilities 
0
0
0
5,413
5,759
6,473
5,947
6,940
7,346
7,426
54,173
38,640
36,129
35,771
38,637
45,159
56,957
58,089
32,727
31,718
29,820
25,337
24,893
27,101
27,10124,89325,33729,82031,71832,72758,08956,95745,15938,63735,77136,12938,64054,1737,4267,3466,9405,9476,4735,7595,413000
       Short-term Debt 
0
0
0
0
1,244
1,227
1,116
1,145
1,176
1,206
1,502
1,540
1,578
1,618
1,658
1,699
1,741
1,783
1,827
1,871
1,915
1,961
2,097
1,747
1,7472,0971,9611,9151,8711,8271,7831,7411,6991,6581,6181,5781,5401,5021,2061,1761,1451,1161,2271,2440000
       Short Long Term Debt 
0
0
0
0
1,244
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,2440000
       Accounts payable 
0
0
0
1,417
1,651
1,080
763
709
684
952
1,405
953
1,281
2,108
2,152
2,100
3,364
4,227
3,645
4,280
4,376
5,868
5,169
6,598
6,5985,1695,8684,3764,2803,6454,2273,3642,1002,1522,1081,2819531,4059526847097631,0801,6511,417000
       Other Current Liabilities 
0
0
0
3,996
106
89
76
63
57
45
6,419
8,534
7,762
9,913
11,892
12,320
12,628
16,230
16,988
16,999
17,274
14,690
16,188
18,756
18,75616,18814,69017,27416,99916,98816,23012,62812,32011,8929,9137,7628,5346,41945576376891063,996000
   > Long-term Liabilities 
0
0
0
140,076
6,587
6,277
5,978
5,661
5,342
5,026
51,782
61,355
56,842
52,370
43,178
34,674
13,243
10,597
9,411
6,796
1,116
611
0
1,125
1,12506111,1166,7969,41110,59713,24334,67443,17852,37056,84261,35551,7825,0265,3425,6615,9786,2776,587140,076000
       Other Liabilities 
0
0
0
0
89
60
52
34
21
16
46,198
56,172
52,069
48,014
39,254
31,192
10,212
8,025
7,314
5,185
0
0
0
0
00005,1857,3148,02510,21231,19239,25448,01452,06956,17246,1981621345260890000
       Deferred Long Term Liability 
0
0
0
0
1,772
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,7720000
> Total Stockholder Equity
-15,739
0
0
-48,948
80,329
120,608
110,406
100,400
89,103
172,058
195,429
198,274
233,126
240,260
317,629
301,514
288,667
269,321
368,769
349,455
333,810
501,609
508,049
621,090
621,090508,049501,609333,810349,455368,769269,321288,667301,514317,629240,260233,126198,274195,429172,05889,103100,400110,406120,60880,329-48,94800-15,739
   Common Stock
0
0
0
0
1
2
2
2
2
3
3
3
3
3
4
4
4
4
5
5
5
6
6
7
766555444433333222210000
   Retained Earnings Total Equity000-259,043-235,403-211,202-212,817-190,761-176,748-158,536-146,954-136,007-126,98600000000000
   Accumulated Other Comprehensive Income 
0
0
0
-31
8
37
78
65
-2,849
57
35
7
-4,276
-4
-50
-712
-2,804
-3,629
-4,002
-2,871
-1,405
-1,179
-750
562
562-750-1,179-1,405-2,871-4,002-3,629-2,804-712-50-4-4,27673557-2,8496578378-31000
   Capital Surplus 
0
0
0
0
2,015
191,310
192,036
192,824
193,635
0
0
325,250
369,130
387,215
476,211
478,970
482,228
485,763
583,968
587,724
594,253
0
0
0
000594,253587,724583,968485,763482,228478,970476,211387,215369,130325,25000193,635192,824192,036191,3102,0150000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
1,599
140,405
57,952
69,705
192,824
193,635
288,923
317,242
198,264
369,130
387,215
476,211
478,970
482,228
485,763
583,968
587,724
594,253
789,751
823,202
968,885
968,885823,202789,751594,253587,724583,968485,763482,228478,970476,211387,215369,130198,264317,242288,923193,635192,82469,70557,952140,4051,599000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue23,385
Cost of Revenue-4,008
Gross Profit19,37719,377
 
Operating Income (+$)
Gross Profit19,377
Operating Expense-157,814
Operating Income-134,429-138,437
 
Operating Expense (+$)
Research Development129,508
Selling General Administrative28,306
Selling And Marketing Expenses0
Operating Expense157,814157,814
 
Net Interest Income (+$)
Interest Income21,468
Interest Expense-21,468
Other Finance Cost-21,468
Net Interest Income21,468
 
Pretax Income (+$)
Operating Income-134,429
Net Interest Income21,468
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-112,961-155,897
EBIT - interestExpense = -155,897
-112,961
-91,493
Interest Expense21,468
Earnings Before Interest and Taxes (EBIT)-134,429-91,493
Earnings Before Interest and Taxes (EBITDA)-130,421
 
After tax Income (+$)
Income Before Tax-112,961
Tax Provision-0
Net Income From Continuing Ops-112,961-112,961
Net Income-112,961
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses157,814
Total Other Income/Expenses Net21,468-21,468
 

Technical Analysis of Ideaya Biosciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ideaya Biosciences Inc. The general trend of Ideaya Biosciences Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ideaya Biosciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ideaya Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 40.70 < 43.84 < 46.40.

The bearish price targets are: 33.46 > 33.24 > 30.12.

Tweet this
Ideaya Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ideaya Biosciences Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ideaya Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ideaya Biosciences Inc. The current macd is -1.41750634.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ideaya Biosciences Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Ideaya Biosciences Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Ideaya Biosciences Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Ideaya Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartIdeaya Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ideaya Biosciences Inc. The current adx is 23.38.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ideaya Biosciences Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Ideaya Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ideaya Biosciences Inc. The current sar is 42.23.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Ideaya Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ideaya Biosciences Inc. The current rsi is 39.97. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Ideaya Biosciences Inc Daily Relative Strength Index (RSI) ChartIdeaya Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ideaya Biosciences Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ideaya Biosciences Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Ideaya Biosciences Inc Daily Stochastic Oscillator ChartIdeaya Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ideaya Biosciences Inc. The current cci is -118.90635394.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Ideaya Biosciences Inc Daily Commodity Channel Index (CCI) ChartIdeaya Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ideaya Biosciences Inc. The current cmo is -21.09189376.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ideaya Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartIdeaya Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ideaya Biosciences Inc. The current willr is -66.36941271.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Ideaya Biosciences Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Ideaya Biosciences Inc Daily Williams %R ChartIdeaya Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ideaya Biosciences Inc.

Ideaya Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ideaya Biosciences Inc. The current atr is 1.7535739.

Ideaya Biosciences Inc Daily Average True Range (ATR) ChartIdeaya Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ideaya Biosciences Inc. The current obv is 45,047,559.

Ideaya Biosciences Inc Daily On-Balance Volume (OBV) ChartIdeaya Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ideaya Biosciences Inc. The current mfi is 49.83.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Ideaya Biosciences Inc Daily Money Flow Index (MFI) ChartIdeaya Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ideaya Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Ideaya Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ideaya Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.965
Ma 20Greater thanMa 5041.314
Ma 50Greater thanMa 10043.578
Ma 100Greater thanMa 20040.501
OpenGreater thanClose38.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ideaya Biosciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Ideaya Biosciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ideaya Biosciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ideaya Biosciences Inc

I send you an email if I find something interesting about Ideaya Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ideaya Biosciences Inc.

Receive notifications about Ideaya Biosciences Inc in your mailbox!